Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsRocky Mountain Health Plans Lumakras PA | OpenPaye…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy N/A

    Lumakras (sotorasib) Coverage

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization of Lumakras for eligible members, including coverage criteria by cancer diagnosis and age.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyLumakras (sotorasib) Coverage
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the applicable cancer diagnosis, KRAS G12C-positive tumor status, and required prior systemic therapy for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Annual review updated coverage criteria for non-small cell lung cancer, pancreatic adenocarcinoma, ampullary adenocarcinoma, colon cancer, rectal cancer, and small bowel adenocarcinoma.

    Criteria were added for appendiceal neoplasms and cancers.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsAuthorization period
    <19Automatic processing age
    KRAS G12CRequired tumor mutation
    4Adult coverage sections
    No progressionReauthorization requirement

    Coverage Criteria

    Patients Less Than 19 Years of Age

    Lumakras will be approved when the following criterion is met:

    Member is less than 19 years of age

    Authorization will be issued for 12 months.

    Non-Small Cell Lung Cancer (NSCLC) — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of non-small cell lung cancer (NSCLC)
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Non-Small Cell Lung Cancer (NSCLC) — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Pancreatic Adenocarcinoma — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of pancreatic adenocarcinoma
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Pancreatic Adenocarcinoma — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Authorization will be issued for 12 months.

    Ampullary Adenocarcinoma — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of ampullary adenocarcinoma
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Ampullary Adenocarcinoma — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Colon Cancer — Initial Authorization

    Lumakras will be approved when BOTH of the following criteria are met:

    BOTH of the following

    • Diagnosis of colon cancer
    • Tumor is KRAS G12C-mutation positive

    Colon Cancer — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Authorization will be issued for 12 months.

    Rectal Cancer — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of rectal cancer
    • Tumor is KRAS G12C-mutation positive

    Rectal Cancer — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Central Nervous System Cancers — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of brain metastases
    • Metastases from KRAS G12C-mutated positive non-small cell lung cancer

    Central Nervous System Cancers — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Authorization will be issued for 12 months.

    Small Bowel Adenocarcinoma — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of small bowel adenocarcinoma
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Small Bowel Adenocarcinoma — Reauthorization

    Lumakras will be approved when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Appendiceal Neoplasms and Cancers — Initial Authorization

    Lumakras will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of appendiceal neoplasm or cancer
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Initial Therapy

    The initial therapy criterion is:

    Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)

    Reauthorization

    Lumakras will be approved for reauthorization when the following continuation criterion is met:

    Patient does not show evidence of progressive disease while on Lumakras therapy

    Authorization will be issued for 12 months.

    NCCN Recommended Regimens

    Lumakras is covered when the following criterion is met:

    The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B

    Provider Actions and Authorization Requirements

    Prior Authorization

    Members Younger Than 19

    For members younger than 19 years, Lumakras will process automatically without a coverage review when the age criterion is met. Approved authorization is issued for 12 months.

    • Member is less than 19 years of age.
    • No coverage review is required for this age group.
    Documentation Required

    NSCLC Initial Authorization

    For initial authorization in NSCLC, document the diagnosis, a KRAS G12C-positive tumor, and receipt of at least one prior systemic therapy.

    • Diagnosis of non-small cell lung cancer (NSCLC).
    • Tumor is KRAS G12C-mutation positive.
    • Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapy.

    Drug and Indication Background

    Lumakras (sotorasib) is an inhibitor of the RAS GTPase family. It is indicated for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This indication received accelerated approval based on overall response rate (ORR) and duration of response (DOR); continued approval may depend on confirmation and description of clinical benefit in confirmatory trials.

    Lumakras is also indicated in combination with panitumumab for adults with KRAS G12C-mutated metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. NCCN recommends Lumakras for additional KRAS G12C-mutated cancers and disease settings, including ampullary adenocarcinoma, appendiceal neoplasms and cancers, pancreatic adenocarcinoma, small bowel adenocarcinoma, and limited or extensive brain metastases.

    Abbreviations and Definitions

    Definitions
    NSCLCNon-small cell lung cancer
    Definitions
    mCRCMetastatic colorectal cancer
    Definitions
    ORROverall response rate
    Definitions
    DORDuration of response

    Initial Therapy Criteria

    NSCLC initial therapy

    Covered when ALL of the following are met.

    • Diagnosis of non-small cell lung cancer (NSCLC)
    • Tumor is KRAS G12C-mutation positiveKRAS G12C positive
    • Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapyAt least 1 prior systemic therapy

    Pancreatic adenocarcinoma initial therapy

    Covered when ALL of the following are met.

    Continuation and Reauthorization Criteria

    Reauthorization

    Reauthorization is available when the patient does not show evidence of progressive disease while on Lumakras therapy.

    Continuation therapy: Patient does not show evidence of progressive disease while on Lumakras therapyNo progressive disease

    Lumakras reauthorization

    Reauthorization will be approved when the following criterion is met.

    Continuation of Lumakras therapy: Patient does not show evidence of progressive disease while on Lumakras therapyNo progressive disease

    Authorization will be issued for 12 months.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyLumakras (sotorasib) Coverage
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the applicable cancer diagnosis, KRAS G12C-positive tumor status, and required prior systemic therapy for initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RequirementsDrug and Indication BackgroundAbbreviations and DefinitionsInitial Therapy CriteriaContinuation and Reauthorization Criteria
  1. Authorization is issued for 12 months.
  2. Documentation Required

    NSCLC Reauthorization

    For NSCLC reauthorization, document that the patient has no evidence of progressive disease while receiving Lumakras. Authorization is issued for 12 months.

    • Patient does not show evidence of progressive disease while on Lumakras therapy.
    • Authorization is issued for 12 months.
    Documentation Required

    Pancreatic Adenocarcinoma Initial Authorization

    For initial authorization in pancreatic adenocarcinoma, document the diagnosis, a KRAS G12C-positive tumor, and receipt of at least one prior systemic therapy.

    • Diagnosis of pancreatic adenocarcinoma.
    • Tumor is KRAS G12C-mutation positive.
    • Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapy.
    • Authorization is issued for 12 months.
    Documentation Required

    Pancreatic Adenocarcinoma Reauthorization

    For pancreatic adenocarcinoma reauthorization, document that the patient has no evidence of progressive disease while receiving Lumakras. Authorization is issued for 12 months.

    • Patient does not show evidence of progressive disease while on Lumakras therapy.
    • Authorization is issued for 12 months.
    Documentation Required

    Ampullary Adenocarcinoma Initial Authorization

    For initial authorization in ampullary adenocarcinoma, document the diagnosis, a KRAS G12C-positive tumor, and receipt of at least one prior systemic therapy.

    • Diagnosis of ampullary adenocarcinoma.
    • Tumor is KRAS G12C-mutation positive.
    • Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapy.
    • Authorization is issued for 12 months.
    Documentation Required

    Ampullary Adenocarcinoma Reauthorization

    For ampullary adenocarcinoma reauthorization, document that the patient has no evidence of progressive disease while receiving Lumakras. Authorization is issued for 12 months.

    • Patient does not show evidence of progressive disease while on Lumakras therapy.
    • Authorization is issued for 12 months.
    Documentation Required

    Colon Cancer Initial Authorization

    For initial authorization in colon cancer, document both the diagnosis and a KRAS G12C-positive tumor. Authorization is issued for 12 months.

    • Diagnosis of colon cancer.
    • Tumor is KRAS G12C-mutation positive.
    • Authorization is issued for 12 months.
    Documentation Required

    Colon Cancer Reauthorization

    For colon cancer reauthorization, document that the patient has no evidence of progressive disease while receiving Lumakras. Authorization is issued for 12 months.

    • Patient does not show evidence of progressive disease while on Lumakras therapy.
    • Authorization is issued for 12 months.

    Unsupported block type: prior_auth

    Documentation Required

    Prior Systemic Therapy Required

    For indications requiring prior treatment, document that the patient has received at least one prior systemic therapy before requesting initial authorization.

    • Examples include an immune checkpoint inhibitor or platinum-based chemotherapy.
    Documentation Required

    NCCN-Recognized Indication

    The indication must be recognized for treatment by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

    • Confirm NCCN recognition of the cancer indication.
    • Accepted NCCN Categories of Evidence and Consensus: 1, 2A, or 2B.
    Documentation Required

    Document Diagnosis, Mutation, and Prior Treatment

    For initial authorization, submit supporting documentation establishing the applicable cancer diagnosis and KRAS G12C mutation status; for indications that require it, also document at least one prior systemic therapy.

    • Diagnosis documentation is required.
    • Laboratory or pathology documentation of a KRAS G12C-mutation-positive tumor is required.
    • For NSCLC, pancreatic adenocarcinoma, and ampullary adenocarcinoma, document at least one prior systemic therapy.
    Documentation Required

    Document Continued Response

    For reauthorization, submit clinical documentation showing that the patient has not developed progressive disease during Lumakras therapy.

    • Document absence of progressive disease while on therapy.
    • This response documentation supports continuation authorization.
    Denial Risk

    Failure to Meet Clinical Criteria

    Initial authorization may be denied when the required clinical criteria are not met or adequately documented.

    • Missing or unsupported diagnosis.
    • Tumor is not documented as KRAS G12C-mutation positive.
    • Required prior systemic therapy is not documented for applicable indications.
    Denial Risk

    Failure to Meet Initial Criteria

    Initial authorization may be denied when the applicable diagnosis, KRAS G12C mutation status, or required prior-treatment criteria are not met.

    • Diagnosis must match a covered indication.
    • Tumor must be documented as KRAS G12C-mutation positive.
    • At least one prior systemic therapy is required for applicable indications, including NSCLC, pancreatic adenocarcinoma, ampullary adenocarcinoma, and other criteria that specify prior treatment.
    Denial Risk

    Disease Progression During Therapy

    Reauthorization may be denied when the patient shows evidence of progressive disease while receiving Lumakras.

    • Documented progressive disease during therapy is a denial condition for continuation.
    Denial Risk

    Progressive Disease During Therapy

    Reauthorization may be denied when progressive disease is documented during Lumakras therapy.

    • Continuation requires documentation that the patient does not show evidence of progressive disease.
  3. Diagnosis of pancreatic adenocarcinoma
  4. Tumor is KRAS G12C-mutation positiveKRAS G12C positive
  5. Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapyAt least 1 prior systemic therapy
  6. Ampullary adenocarcinoma initial therapy

    Covered when ALL of the following are met.

    • Diagnosis of ampullary adenocarcinoma
    • Tumor is KRAS G12C-mutation positiveKRAS G12C positive
    • Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapyAt least 1 prior systemic therapy

    Colon cancer initial therapy

    Covered when BOTH of the following are met.

    • Diagnosis of colon cancer
    • Tumor is KRAS G12C-mutation positiveKRAS G12C positive

    Rectal Cancer initial therapy

    Initial authorization requires ALL of the following.

    Rectal cancer initial therapy

    • Diagnosis of rectal cancer
    • Tumor is KRAS G12C-mutation positive

    Central Nervous System Cancers initial therapy

    Initial authorization requires BOTH of the following.

    Central nervous system cancers initial therapy

    • Diagnosis of brain metastases
    • Metastases from KRAS G12C-mutated positive non-small cell lung cancer

    Small Bowel Adenocarcinoma initial therapy

    Initial authorization requires ALL of the following.

    Small bowel adenocarcinoma initial therapy

    • Diagnosis of small bowel adenocarcinoma
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapyAt least 1 prior systemic therapy

      Examples include an immune checkpoint inhibitor or platinum-based chemotherapy.

    Appendiceal Neoplasms and Cancers initial therapy

    Initial authorization requires ALL of the following.

    Appendiceal neoplasms and cancers initial therapy

    • Diagnosis of appendiceal neoplasm or cancer
    • Tumor is KRAS G12C-mutation positive
    • Patient has received at least one prior systemic therapyAt least 1 prior systemic therapy

      Examples include an immune checkpoint inhibitor or platinum-based chemotherapy.

    Lumakras initial therapy

    Prior systemic therapy: Patient has received at least one prior systemic therapy, such as an immune checkpoint inhibitor or platinum-based chemotherapy.At least 1 prior systemic therapy

    Lumakras reauthorization

    Reauthorization: Patient does not show evidence of progressive disease while on Lumakras therapyNo evidence of progressive disease